 |
 |
NEW YORK--(BUSINESS WIRE) via NewsEdge Corporation -- Nymox Alzheimer Drug Candidates Based on Spherons Now in Development Offer Exciting New Hope for the Future Scientists from Nymox Pharmaceutical Corporation (NASDAQ National Market: NYMXF; Montreal Exchange: NMX) announced today at the Manhattan Alzheimer's Disease conference in New York City that they believe they have found a major cause of Alzheimer's disease. The peer-reviewed research results appear in the March issue of The Journal of Alzheimer's Disease. The Nymox Pharmaceutical Corporation research team has discovered a new human brain entity called the "spheron" which they say satisfies 20 criteria of validity as a causal entity for Alzheimer's disease. The Company, which has patents on the spherons, their use in diagnostics and therapeutics, as well as the spheron based new chemical entities, has several new drug candidates in development based on the spherons, treatments which may eventually be capable of slowing or stopping the disease. Nymox cautions that the spheron based Nymox Alzheimer candidate drugs, while showing exciting dramatic positive effects in the test tube and in animals, and while showing no toxicity thus far, have not yet been tested in humans. Dr. Paul Averback, CEO of Nymox, said, "The data comes from a wide range of scientific disciplines and represents many years of work. Spherons are quite novel and some skepticism is to be expected. Still, we believe the proof on spherons is overwhelming, and our research on drugs that may slow or stop the disease is showing great potential. We welcome everyone to scrutinize the data in The Journal of Alzheimer's Disease." Spherons are present in every person's brain by the age of one year. They progressively increase in size throughout life until they become so big (one thousand times bigger by age 75 compared to age one) that they burst. According to the Nymox researchers, the bursting spheron then turns into the senile amyloid plaques of Alzheimer's disease. To prove this, the Nymox team first showed that spherons and plaques were located in the exactly identical specific locations in the brain, and that the number of plaques which appears in Alzheimer's disease was equal to the number of spherons which have disappeared. Then they extracted and purified spherons from the brain and showed that spherons contained the marker molecules found in plaques. The Nymox team then showed that spherons always turn into plaques when they are burst in the test tube or when they are injected into experimental animals. In addition, the Nymox researchers provided 20 highly specific criteria of validity linking spherons to Alzheimer's disease. The Nymox drug candidates in development (such as NX-D2858) are capable of blocking the transformation of human spherons into plaques in the test tube and in the experimental animal. These Nymox compounds offer rational hope for treatments that may eventually be capable of slowing or stopping the progression of Alzheimer's disease. This press release contains certain "forward-looking statements", as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. For further information, call Dr. Michael Munzar, Medical Director, at 1-800-93NYMOX or e-mail at [log in to unmask] or visit the Nymox website at http://www.nymox.com, or contact Nymox's Investor Relations Counsel: The Equity Group: Devin Sullivan (212) 836-9608 Dan Bustillos (212) 836-9606 NO REGULATORY AUTHORITY HAS APPROVED NOR DISAPPROVED THE CONTENT OF THIS RELEASE. CONTACT: Nymox Corporation | Michael Munzar, M.D. | Medical Director | (800) 93NYMOX | NYMXF's INVESTOR RELATIONS COUNSEL: | The Equity Group | Devin Sullivan (212) 836-9608 | Dan Bustillos (212) 836-9606